No Data
This Thursday marks the start of the "soul negotiation" for medical insurance. Which companies are likely to be selected?
According to the National Medical Insurance Administration, a press conference will be held at 10 a.m. on November 28 at the National Medical Insurance Administration to announce the adjustments to the national medical insurance pharmaceutical catalog for 2024 and answer questions from reporters. This means that the results of the national negotiation for medical insurance centralized purchasing in 2024 will be announced this Thursday.
InnoCare Pharma Plans New Share Incentive Scheme
Innocare (688428.SH): Proposes to launch a restricted stocks incentive plan for 12.33775 million shares.
Geelong November 26th | Innocare (688428.SH) announced the 2024 star board restricted stocks incentive plan, with the planned number of restricted stocks to be granted to incentive recipients at 12.33775 million shares, accounting for approximately 0.70% of the total number of shares issued by the company at the time of approval by the shareholders' meeting of 1762.567202 million shares under this incentive plan. The total number of incentive recipients to be initially granted under this incentive plan is 79 people, accounting for approximately 7.25% of the total number of employees as of December 31, 2023 of 1,089 people, including those employed by the company at the time of this incentive plan announcement within the company.
Innocare (09969) recommends adopting the RMB stock incentive plan for 2024.
Innocare (09969) announced that the company proposes to adopt the RMB shares for the 2024 shareholders' general meeting...
Many innovative drugs stocks in Hong Kong suddenly soared!
On the morning of November 25, the hang seng index fell slightly, while the Hong Kong stock market's biomedical sector performed well. Notably, several biomedical companies saw their stock prices rise significantly due to recent news of major collaboration advancements.
Innocare (688428): Achieving simultaneous growth in both tumor immunity and self-immunity, the company enters a period of rapid growth.
The market size for NHL and autoimmune disease medications is large, and the application prospects for BTK inhibitors are broad: NHL is a type of malignant tumor originating from the lymphatic system. According to Frost & Sullivan data, it is estimated that by 2030, the number of NHL patients in china will be significant.
No Data
No Data